Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hers vs Teleios Health

Hers
Graded #252

Higher grade

vs+3.8999999999999986
Teleios Health
Graded #331

Lower grade

The verdict

Hers takes it — 63.9/100 to 60/100.

Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleios Health +29
54
83
Dose & formulationHers +13
77
64
Clinical oversightHers +22
71
49
Labs & monitoringHers +4
52
48
FulfillmentHers +39
81
42
Contract termsTeleios Health +14
41
55
Hers · left barTeleios Health · right bar

The numbers

MetricHersTeleios Health
WeighScore63.9/10060/100
GradeCC
Scorecard rank#252#331
Semaglutide$199/mo (starting dose, compounded)$99/mo (starting dose, compounded)
Tirzepatide$299/mo (starting dose, plus a separate fee, brand-name)$139/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Hers

Graded #252 · C

Strengths

  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Teleios Health

Graded #331 · C

Strengths

  • Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
  • Compounded tirzepatide from a competitive $139/mo floor
  • Markets physician (MD/DO) prescribing rather than an NP-only model
  • Clean meta-tag and SEO implementation

Where it loses points

  • Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
  • No named medical director, physician, or corporate entity disclosed
  • Year founded unknown — a newer floor-price entrant warranting extra scrutiny
  • No LegitScript, NABP, or SOC 2 trust signal found
  • Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard